An official website of the United States government
Some ranges are expressed with only 1 decimal place (e.g. 237.0-237.9) while some codes within that range may have two decimal places (e.g. 237.71 and 237.72). All codes in the range are included.
These tables are also available in a printable version (PDF, 579 KB).
Comprehensive ICD-9-CM Casefinding Code List for Reportable Tumors (Effective Date: 1/1/2010)
| ICD-9-CM Code^ | Explanation of Code |
|---|---|
| 140.0 – 208.92 | Malignant Neoplasms |
| 209.00 – 209.29 | Neuroendocrine tumors |
| 209.30 | Malignant poorly differentiated neuroendocrine carcinoma, any site
|
| 209.31 – 209.36 | Merkel cell carcinoma Note: Effective date 10/1/09 |
| 209.70 – 209.79 | Secondary neuroendocrine tumors Note: Effective Date 10/1/09
Note: All neuroendocrine or carcinoid tumors specified as secondary are malignant |
| 225.0 – 225.9 | Benign neoplasm of brain and spinal cord neoplasm |
| 227.3 | Benign neoplasm of pituitary gland and craniopharyngeal duct (pouch)
|
| 227.4 | Benign neoplasm of pineal gland |
| 227.9 | Benign neoplasm; endocrine gland, site unspecified |
| 228.02 | Hemangioma; of intracranial structures
|
| 228.1 | Lymphangioma, any site |
| 230.0 – 234.9 | Carcinoma in situ
|
| 236.0 | Endometrial stroma, low grade (8931/1)
|
| 237.0 – 237.9 | Neoplasm of uncertain behavior [borderline] of endocrine glands and nervous system |
| 238.4 | Polycythemia vera (9950/3) |
| 238.6 | Neoplasm of uncertain behavior of other and unspecified sites and tissues, Plasma cells (Plasmacytoma, extramedullary, 9734/3)
|
| 238.7 | Other lymphatic and hematopoietic tissues Note: This code was expanded 10/2006. It is now a subcategory and is no longer valid for use for coding purposes. It should be included in extract programs for quality control purposes.) |
| 238.71 | Essential thrombocythemia (9962/3)
|
| 238.72 | Low grade myelodysplastic syndrome lesions (includes 9980/3, 9982/3, 9983/3, 9985/3, 9991/3, 9992/3)
|
| 238.73 | High grade myelodysplastic syndrome lesions (includes 9983/3)
|
| 238.74 | Myelodysplastic syndrome with 5q deletion (9986/3)
|
| 238.75 | Myelodysplastic syndrome, unspecified (9985/3, 9987/3, 9989/3) |
| 238.76 | Myelofibrosis with myeloid metaplasia (9961/3)
|
| 238.77 | Polymorphic Post-Transplant Lymphoproliferative Disorder (9971/3) Post transplant lymphoproliferative disorder (9987/3) |
| 238.79 | Other lymphatic and hematopoietic tissues (includes 9759, 9960/3, 9961/3, 9970/1, 9931/3, 9960/3, 9965/3, 9966/3, 9967/3, 9975/3)
|
| 239.6 | Neoplasms of unspecified nature, brain |
| 239.7 | Neoplasms of unspecified nature; endocrine glands and other parts of nervous system |
| 239.81 – 239.89 | Neoplasms of unspecified nature; other specified sites Note: Effective Date 10/1/09 |
| 273.2 | Other paraproteinemias
|
| 273.3 | Macroglobulinemia
|
| 288.3 | Eosinophilia Note: This code is for eosinophilia, which is not reportable. Do not abstract unless diagnosis is “Hypereosinophilic syndrome (9964/3).” |
| 288.4 | Hemophagocytic syndromes
|
| 795.06 | Papanicolaou smear of cervix with cytologic evidence of malignancy |
| 795.16 | Papanicolaou smear of vagina with cytologic evidence of malignancy |
| 796.76 | Papanicolaou smear of anus with cytologic evidence of malignancy |
| V10.0 – V10.89 | Personal history of malignancy Note: Screen for recurrences, subsequent primaries, and/or subsequent treatment |
| V10.90 | Personal history of unspecified malignant neoplasm Note: Effective Date: 10/1/09. Screen for recurrences, subsequent primaries, and/or subsequent treatment |
| V10.91 | Personal history of malignant neuroendocrine tumor, carcinoid tumor, Merkel cell carcinoma Note: Effective Date: 10/1/09. Screen for recurrences, subsequent primaries, and/or subsequent treatment |
| V12.41 | Personal history of benign neoplasm of the brain |
The following codes are not reportable per se, but they should alert registrars to look for the first malignant neoplasm associated with these codes.
Comprehensive ICD-9-CM Casefinding Code List for Reportable Tumors (Effective Date: 1/1/2010), Supplementary List #1-ICD-9-CM Codes that Should Be Followed by or Associated with a Neoplasm Code
| ICD-9-CM Code^ | Explanation of Code |
|---|---|
| 258.02 – 258.03 | Multiple endocrine neoplasia (MEN) type IIA and IIB (rare familial cancer syndrome) Note: Use additional codes to identify any malignancies and other conditions associated with the syndrome |
| 285.22 | Anemia in neoplastic disease Note: Assign also a code for the neoplasm causing the anemia Excludes: anemia due to antineoplastic chemotherapy, new code 285.3 |
| 289.83 | Myelofibrosis (NOS) (9961/3) Note: Not every case of myelofibrosis is associated with a malignancy. Review terms included in ICD-O-3 to determine if case is reportable. See ICD-9-CM |
| 338.3 | Neoplasm related pain (acute, chronic); Cancer associated pain; Pain due to malignancy (primary/secondary); Tumor associated pain |
| 511.81 | Malignant pleural effusion Note : Code first malignant neoplasm if known. If the primary site is not known, code 199.0, disseminated carcinomatosis, or code 199.1, malignancy NOS, should be assigned |
| 789.51 | Malignant ascites Note : Code first malignant neoplasm if known. If the primary site is not known, code 199.0, disseminated carcinomatosis, or code 199.1, malignancy NOS, should be assigned |
NOTE: Cases with these codes should be screened as registry time allows. These are neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm. Experience in the SEER registries has shown that using the supplementary list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases.
Comprehensive ICD-9-CM Casefinding Code List for Reportable Tumors (Effective Date: 1/1/2010), Supplementary List #1-ICD-9-CM Codes that Should Be Followed by or Associated with a Neoplasm Code, Supplementary List #2-ICD-9-CM Code List to Screen for Cancer Cases Not Identified by Other Codes (Effective Date: 1/1/2010)
| ICD-9-CM Code^ | Explanation of Code |
|---|---|
| 042 | Acquired Immunodeficiency Syndrome (AIDS) Note: This is not a malignancy. Medical coders are instructed to add codes for AIDS-associated malignancies. Screen 042 for history of cancers that might not be coded. |
| 079.4 | Human papillomavirus |
| 079.50 – 079.59 | Retrovirus (HTLV, types I, II and 2) |
| 209.40-209.69 | Benign carcinoid tumors |
| 210.0 – 229.9 | Benign neoplasms (except for 225.0-225.9, 227.3, 227.4, 227.9, 228.02, and 228.1, which are listed in the Reportable list) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors. |
| 235.0 – 236.6 | Neoplasms of uncertain behavior (except for 236.0, which is listed in the Reportable list) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors |
| 238.0 – 239.9 | Neoplasms of uncertain behavior (except for 238.4, 238.6, 238.71-238.79, 239.6, 239.7, 239.81 and 239.89, which are listed in the Reportable list) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors |
| 253.6 | Syndrome of inappropriate secretion of antidiuretic hormone Note: Part of the paraneoplastic syndrome. See note of explanation in the “notes” section. |
| 259.2 | Carcinoid Syndrome |
| 259.8 | Other specified endocrine disorders |
| 273.0 | Polyclonal hypergammaglobulinemia (Waldenstrom) Note: Review for miscodes |
| 273.1 | Monoclonal gammopathy of undetermined significance (9765/1) Note: Screen for incorrectly coded Waldenstrom macroglobulinemia or progression |
| 273.9 | Unspecified disorder of plasma protein metabolism Note: Screen for incorrectly coded Waldenstrom’s macroglobulinemia |
| 275.42 | Hypercalcemia Note: Part of the paraneoplastic syndrome. See note of explanation in the “notes” section. |
| 277.88 | Tumor lysis syndrome/Tumor lysis syndrome following antineoplastic drug therapy Note: Effective Date: 10/1/09 |
| 279.00 | Hypogammaglobulinemia Note: Predisposed to lymphoma or stomach cancer |
| 279.02 – 279.06 | Selective IgM immunodeficiency Note: Associated with lymphoproliferative disorders |
| 279.10 | Immunodeficiency with predominant T-cell defect, NOS |
| 279.12 | Wiskott-Aldrich Syndrome |
| 279.13 | Nezelof’s Syndrome |
| 279.2 – 279.9 | Combined immunity deficiency – Unspecified disorder of immune mechanism |
| 284.81 | Red cell aplasia (acquired, adult, with thymoma) |
| 284.89 | Other specified aplastic anemias due to drugs (chemotherapy or immunotherapy), infection, radiation |
| 284.9 | Aplastic anemia, unspecified Note: Review for miscodes |
| 285.0 | Sideroblastic anemia |
| 285.3 | Antineoplastic chemotherapy induced anemia (Anemia due to antineoplastic chemotherapy) Note: Effective Date: 10/1/09 |
| 288.03 | Drug induced neutropenia |
| 289.89 | Other specified diseases of blood and blood-forming organs Note: Review for miscodes |
| 323.81 | Encephalomyelitis; specified cause NEC Note: Part of the paraneoplastic syndrome. See note of explanation in the “notes” section. |
| 379.59 | Opsoclonia Note: Part of the paraneoplastic syndrome. See note of explanation in the “notes” section. |
| 528.01 | Mucositis due to antineoplastic therapy |
| 630 | Hydatidiform Mole (9100/0) Note: This is a benign tumor that can become malignant. If malignant, it should be reported as Choriocarcinoma (9100/3) and will have a malignancy code in the 140-209 range. |
| 686.01 | Pyoderma gangrenosum Note: Part of the paraneoplastic syndrome. See note of explanation in the “notes” section. |
| 695.89 | Sweet’s syndrome Note: Part of the paraneoplastic syndrome. See note of explanation in the “notes” section. |
| 701.2 | Acanthosis nigricans Note: Part of the paraneoplastic syndrome. See note of explanation in the “notes” section. |
| 710.3 | Dermatomyositis Note: Part of the paraneoplastic syndrome. See note of explanation in the “notes” section. |
| 710.4 | Polymyositis Note: Part of the paraneoplastic syndrome. See note of explanation in the “notes” section. |
| 785.6 | Enlargement of lymph nodes |
| 790.93 | Elevated prostate specific antigen [PSA] |
| 795.8 | Abnormal tumor markers; Elevated tumor associated antigens [TAA]; Elevated tumor specific antigens [TSA]; Excludes: Elevated prostate specific antigen [PSA] (790.93) |
| 795.81 | Elevated carcinoembryonic antigen [CEA] |
| 795.82 | Elevated cancer antigen 125 [CA 125] |
| 795.89 | Other abnormal tumor markers |
| 999.31 | Infection due to central venous catheter (porta-cath) |
| 999.81 | Extravasation of vesicant chemotherapy |
| E879.2 | Adverse effect of radiation therapy |
| E930.7 | Adverse effect of antineoplastic therapy |
| E933.1 | Adverse effect of immunosuppressive drugs |
| V07.31, V07.39 | Other prophylactic chemotherapy |
| V07.8 | Other specified prophylactic measure |
| V12.72 | Colonic polyps (history of) |
| V15.3 | Irradiation: previous exposure to therapeutic or ionizing radiation |
| V42.81 | Organ or tissue replaced by transplant, Bone marrow transplant |
| V42.82 | Transplant; Peripheral stem cells |
| V51.0 | Encounter for breast reconstruction following mastectomy |
| V52.4 | Breast prosthesis and implant |
| V54.2 | Aftercare for healing pathologic fracture |
| V58.0 | Encounter for radiation therapy |
| V58.1 | Encounter for antineoplastic chemotherapy and immunotherapy Note: This code was discontinued as of 10/2006 but should be included in extract programs for quality control purposes |
| V58.11 | Encounter for antineoplastic chemotherapy |
| V58.12 | Encounter for antineoplastic immunotherapy |
| V58.42 | Aftercare following surgery for neoplasm |
| V66.1 | Convalescence following radiotherapy |
| V66.2 | Convalescence following chemotherapy |
| V67.1 | Radiation therapy follow up |
| V67.2 | Chemotherapy follow up |
| V71.1 | Observation for suspected malignant neoplasm |
| V76.0 – V76.9 | Special screening for malignant neoplasm |
| V78.0 – V78.9 | Special screening for disorders of blood and blood-forming organs |
| V82.71 | Screening for genetic disease carrier status |
| V82.79 | Other genetic screening |
| V82.89 | Genetic screening for other specified conditions |
| V82.9 | Genetic screening for unspecified condition |
| V84.01 – V84.09 | Genetic susceptibility to malignant neoplasm |
| V84.81 | Genetic susceptibility to multiple endocrine neoplasia [MEN] |
| V86.0 | Estrogen receptor positive status [ER+] |
| V86.1 | Estrogen receptor negative status [ER-] |
| V87.41 | Personal history of antineoplastic chemotherapy |
NOTES:
- Prostatic Intraepithelial Neoplasia (PIN III) M-8148/2 is not required by SEER.
- Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior a /3 (malignant) .
- Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER.
- These diseases are part of the paraneoplastic syndrome. “Paraneoplastic syndrome isn’t cancer. It’s a disease or symptom that is the consequence of cancer but is not due to the local presence of cancer cells. A paraneoplastic syndrome may be the first sign of cancer.”
^ International Classification of Diseases, Ninth Revision, Clinical Modification, 2009.
